Certara, Inc. (CERT)
| Market Cap | 2.79B |
| Revenue (ttm) | 324.36M |
| Net Income (ttm) | -4.14M |
| Shares Out | 157.14M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | 32.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 781,673 |
| Open | 17.35 |
| Previous Close | 17.47 |
| Day's Range | 17.31 - 17.82 |
| 52-Week Range | 10.6 - 29.99 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 20.97 (+18.3%) |
| Earnings Date | Nov 7, 2022 |
About CERT
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosim... [Read more]
Financial Performance
In 2021, Certara's revenue was $286.10 million, an increase of 17.48% compared to the previous year's $243.53 million. Losses were -$13.27 million, -73.14% less than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for CERT stock is "Buy." The 12-month stock price forecast is 20.97, which is an increase of 18.34% from the latest price.
News
Why Certara's Shares Rose 37.7% This Week
The company, which helps other companies in their drug development, reported strong third-quarter numbers.
Certara, Inc. (CERT) Q3 Earnings Miss Estimates
Certara, Inc. (CERT) delivered earnings and revenue surprises of -9.09% and 2.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara Reports Third Quarter 2022 Financial Results
Biosimulation software and services fuel third quarter growth Biosimulation software and services fuel third quarter growth
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase
Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares Arsenal will acquire approximately 30M shares ...
Certara to Participate in Upcoming Investor Conferences
PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conf...
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Software for Evaluating Regula...
The PMDA enters 9th consecutive year of using Certara's software The PMDA enters 9th consecutive year of using Certara's software
Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022
PRINCETON, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 af...
Here's Why Certara Stock Is Falling Friday
Certara Inc (NASDAQ: CERT) shares are trading lower by 15.40% to $17.08 Friday morning after the company announced a secondary offering of 7 million shares of common stock. What Else?
Certara Announces Secondary Offering
PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) (“Certara”), a global leader in biosimulation, today announced the sale by certain stockholders (the “Selling Stockholders...
Certara, Inc. (CERT) Q2 Earnings and Revenues Miss Estimates
Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara Reports Second Quarter 2022 Financial Results
Biosimulation software and services fuel second quarter growth Biosimulation software and services fuel second quarter growth
Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module
New automation, analytics and collaboration features save time and ensure regulatory compliance New automation, analytics and collaboration features save time and ensure regulatory compliance
Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell Therapies
Certara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR T-cell therapies Certara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR...
Certara Appoints Rosemary Crane as New Independent Board Member
PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective ...
Certara Appoints Eran Broshy as New Independent Board Member
PRINCETON, N.J., July 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective Jul...
Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022
PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2022 a...
Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development
Advances lead optimization, first-in-human dose prediction and formulation development Advances lead optimization, first-in-human dose prediction and formulation development
Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics
New capabilities enhance clinical predictability for different compounds across more therapeutic areas New capabilities enhance clinical predictability for different compounds across more therapeutic areas
Certara, Inc. (CERT) Matches Q1 Earnings Estimates
Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara Reports First Quarter 2022 Financial Results
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022.
Certara to Report First Quarter 2022 Financial Results on May 5th, 2022
PRINCETON, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2022 a...
Certara, Inc. (CERT) Soars 6.1%: Is Further Upside Left in the Stock?
Certara, Inc. (CERT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...
Why Certara Shares Are Plunging Today
Certara Inc's (NASDAQ: CERT) Q4 FY21 sales increased 17% to $75.3 million, missing the consensus of $83.26 million. The increase was driven by $6.1 million in revenue from Pinnacle 21, acquired in Q4 f ...
Certara, Inc. (CERT) Q4 Earnings and Revenues Lag Estimates
Certara, Inc. (CERT) delivered earnings and revenue surprises of -88.89% and 8.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Certara Reports Fourth Quarter and Full Year 2021 Financial Results
PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021 and ...